| Circadian clock: Time for novel anticancer strategies? L Ercolani, A Ferrari, C De Mei, C Parodi, M Wade, B Grimaldi Pharmacological research 100, 288-295, 2015 | 42 | 2015 |
| Synthesis and in vitro anticancer activity of the first class of dual inhibitors of REV-ERBβ and autophagy E Torrente, C Parodi, L Ercolani, C De Mei, A Ferrari, R Scarpelli, ... Journal of medicinal chemistry 58 (15), 5900-5915, 2015 | 33 | 2015 |
| SiCoDEA: a simple, fast and complete app for analyzing the effect of individual drugs and their combinations G Spinozzi, V Tini, A Ferrari, I Gionfriddo, R Ranieri, F Milano, ... Biomolecules 12 (7), 904, 2022 | 9 | 2022 |
| Abstract P195: Omacetaxine mepessucinate plus venetoclax show strong synergistic anti-leukemic activity in nucleophosmin (NPM1)-mutated AML patient-derived … F Mezzasoma, V Cardinali, I Gionfriddo, F Milano, S Sciabolacci, A Ferrari, ... Molecular Cancer Therapeutics 20 (12_Supplement), P195-P195, 2021 | 1 | 2021 |
| Poster: AML-377 A “Designed” High-Throughput Drug Screening Strategy Identifies Aurora Kinase A Inhibitors as Promising Preclinical Candidates for the Treatment of NPM1-Mutated AML R Ranieri, M Neuenschwander, S Kleissle, F Mezzasoma, S Silvestri, ... Clinical Lymphoma, Myeloma and Leukemia 22, S134, 2022 | | 2022 |
| AML-377 A “Designed” High-Throughput Drug Screening Strategy Identifies Aurora Kinase A Inhibitors as Promising Preclinical Candidates for the Treatment of NPM1-Mutated AML R Ranieri, M Neuenschwander, S Kleissle, F Mezzasoma, S Silvestri, ... Clinical Lymphoma Myeloma and Leukemia 22, S242, 2022 | | 2022 |
| A" DESIGNED" HIGH THROUGHPUT DRUG SCREENING STRATEGY IDENTIFIES AURORA KINASE A INHIBITORS AS PROMISING PRECLINICAL CANDIDATES FOR THE TREATMENT OF NPM1-MUTATED AML R Ranieri, M Neuenschwander, S Kleissle, F Mezzasoma, S Silvestri, ... HAEMATOLOGICA 107, 20-20, 2022 | | 2022 |
| SiCoDEA: A Simple, Fast and Complete App for Analyzing the Effect of Individual Drugs and Their Combinations. Biomolecules 2022, 12, 904 G Spinozzi, V Tini, A Ferrari, I Gionfriddo, R Ranieri, F Milano, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| Omacetaxine mepessucinate plus venetoclax show strong synergistic anti-leukemic activity in nucleophosmin (NPM1)-mutated AML patient-derived xenograft (PDX) models to support a … F Mezzasoma, V Cardinali, I Gionfriddo, F Milano, S Sciabolacci, A Ferrari, ... MOLECULAR CANCER THERAPEUTICS 20 (12), 2021 | | 2021 |
| Combination anticancer endowed with antitumor activity, comprising alkaloids of chelidonium majus R Batistoni, AMP Bianucci, A Ferrari, P Madau, G Lubinu, S Marracci, ... US Patent App. 15/547,330, 2019 | | 2019 |
| Multi-target inhibitors of circadian clock and autophagy as a novel anticancer approach. A FERRARI | | 2018 |
| Identification of a novel class of lysosomotropic Rev-erb antagonist as an innovative anticancer strategy C Parodi, L Ercolani, C De Mei, A Ferrari, E Torrente, R Scarpelli, ... The Febs Journal 282, 261, 2015 | | 2015 |
| Aiming to understand the mechanisms underlying the different responses to berberine among different cell lines ME Isolani, M Natali, R Batistoni, A Ferrari, AMP Bianucci, S Marracci PROCEEDINGS OF THE 61ST CONGRESS OF THE ITALIAN EMBRYOLOGICAL GROUP (GEI …, 2015 | | 2015 |
| Dynamic intracellular localization of natural alkaloids in different human tumor cell lines: a case study with berberine M Natali, S Marracci, R Batistoni, P Deri, A Ferrari, AM Bianucci 13th FISV Congress, 90-90, 2014 | | 2014 |
